Boston Scientific (NYSE:BSX) Updates FY 2026 Earnings Guidance

Boston Scientific (NYSE:BSX) issued an update on its FY 2026 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 3.340-3.410 for the period, compared to the consensus earnings per share estimate of 3.450. The company issued revenue guidance of $21.5 billion-$21.8 billion, compared to the consensus revenue estimate of $22.2 billion. Boston Scientific also updated its Q2 2026 guidance to 0.820-0.840 EPS.

Boston Scientific Price Performance

BSX opened at $65.89 on Friday. The stock has a 50-day moving average price of $68.71 and a 200-day moving average price of $86.02. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. The firm has a market cap of $97.93 billion, a PE ratio of 27.57, a P/E/G ratio of 1.03 and a beta of 0.78. Boston Scientific has a 1 year low of $59.38 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a return on equity of 19.68% and a net margin of 17.29%.Boston Scientific’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Sell-side analysts predict that Boston Scientific will post 3.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BSX. TD Cowen decreased their target price on Boston Scientific from $115.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. Evercore decreased their target price on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating for the company in a research report on Thursday, February 5th. Mizuho decreased their target price on Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a research report on Monday, April 13th. BTIG Research decreased their target price on Boston Scientific from $90.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Robert W. Baird decreased their target price on Boston Scientific from $86.00 to $78.00 and set an “outperform” rating for the company in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $93.91.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.34% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q1 beat on sales and EPS: BSX reported roughly $5.20B in Q1 revenue (up ~11.6% YoY) and adjusted EPS of $0.80, topping Street sales and matching/edging EPS expectations—showing continued demand for core cardiology devices. Article Title
• Positive Sentiment: Shares rallied after the “reset”: the market interpreted the combination of a beat plus a deliberate guidance reset as a potential reset-for-outperformance trade, driving intraday gains following the release. Article Title
• Positive Sentiment: Elevated bullish options flow: traders bought a high volume of BSX call options around earnings, signaling speculative/hedged bullish positioning into the post-earnings move. Article Title
• Neutral Sentiment: Analysts cut price targets but largely kept buy/overweight ratings—banks trimmed PTs (Barclays, Jefferies, Truist, Baird, Needham) reflecting the lower guide while still pointing to mid/long-term upside. This reduces near-term sentiment but preserves institutional support. Article Title
• Neutral Sentiment: Street views call the guidance reset “prudent” and expect a Q2 trough; some analysts see the pullback as a buying opportunity if long-term growth drivers (EP, structural heart, etc.) remain intact. Article Title
• Negative Sentiment: Guidance cut and trimmed growth: management lowered FY2026 EPS and revenue guidance, citing specific product/segment headwinds—this is the primary reason for elevated volatility and lowered Street estimates. Article Title
• Negative Sentiment: Multiple securities class-action and investor-alert filings and law-firm investigations tied to the July 2025–Feb 2026 period create legal overhang and could increase uncertainty/expense for shareholders. Article Title
• Negative Sentiment: Short-term downside signals: some outlets flagged BSX hitting 52-week lows and several firms further trimmed forecasts—heightening near-term technical/psychological pressure. Article Title

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC grew its stake in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after acquiring an additional 226 shares during the period. DV Equities LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at approximately $197,000. Sunbelt Securities Inc. grew its stake in shares of Boston Scientific by 33.0% during the 4th quarter. Sunbelt Securities Inc. now owns 1,411 shares of the medical equipment provider’s stock valued at $135,000 after acquiring an additional 350 shares during the period. Prosperity Bancshares Inc bought a new position in shares of Boston Scientific during the 4th quarter valued at approximately $111,000. Finally, Quattro Advisors LLC bought a new position in shares of Boston Scientific during the 4th quarter valued at approximately $105,000. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.